The 3 most recent market catalysts affecting $GENB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a 'Buy' rating and a $30 price target for Generate Biomedicines (GENB). This action signals that the analyst firm maintain…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Generate Biomedicines (GENB) and raised the price target from $25 to $30. This action signals contin…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (GENB) released its Q2 earnings, showing a mixed performance. While the company managed to beat EPS estimates, reporting a loss of $(0.52) against an expected…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.